Trial Profile
Open-Label Study to Evaluate the Safety and Pharmacokinetics of Single-and Multiple-Dose Extended-Release OROS Paliperidone in Pediatric Subjects (>/= 10 to </= 17 Years of Age) with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2011
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen-Cilag
- 26 May 2011 New trial record